Celltrion's Biosimilar Gets FDA Panel Nod Despite Extrapolation Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee discussion reflects tension between desire for indication-specific efficacy data and recognition of benefits of 351(k) pathway.
You may also be interested in...
Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval
Much like it did for the first biosimilars, US FDA approved Yescarta without an advisory committee, as Novartis' first-in-class CAR-T cell therapy already set the stage for an agency review.
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Pink Sheet's Drug Review Profile reveals FDA's second biosimilar got hung up on product quality concerns that suggested potential differences between Celltrion's CT-P13 and its reference biologic, Janssen's infliximab.